Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Fineline Cube Feb 9, 2026
Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Fineline Cube Feb 9, 2026
Company Digital

Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss

Fineline Cube Jul 6, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...

Company Policy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Fineline Cube Jul 6, 2022

Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...

Policy / Regulatory R&D

CDE Releases 60th Batch of Chemical Generic Reference Preparations

Fineline Cube Jul 6, 2022

The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...

Company Deals

Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies

Fineline Cube Jul 5, 2022

China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...

Company Deals

Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development

Fineline Cube Jul 5, 2022

China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...

Company Deals

Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM

Fineline Cube Jul 5, 2022

China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...

Drug

Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China

Fineline Cube Jul 5, 2022

Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...

Company Drug

InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies

Fineline Cube Jul 5, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...

Company Drug

Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...

Company Deals

Techbank Medical Closes RMB 100M Series A to Build Global Innovation Platform

Fineline Cube Jul 5, 2022

Shanghai Techbank Medical Technology Co., Ltd, a cardiovascular device maker, has reportedly closed its Series...

Company Deals

PackGene and Genemagic Partner on AAV Production and CDMO Services

Fineline Cube Jul 5, 2022

China-based PackGene LLC has entered into a partnership with compatriot firm Genemagic Biosciences Co., Ltd....

Company Drug

PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...

Company Drug

Akeso Biopharma’s Cadonilimab Achieves National Delivery in China

Fineline Cube Jul 5, 2022

China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...

Company Drug

Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...

Company Drug

Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia

Fineline Cube Jul 5, 2022

China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...

Policy / Regulatory

Guangdong Releases 2022 Non-Immunization Vaccine Catalog (7th Batch)

Fineline Cube Jul 5, 2022

The Guangdong Provincial Center for Disease Control and Prevention and Guangdong Medicine Exchange jointly released...

Company

WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing

Fineline Cube Jul 5, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Company Drug

JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma

Fineline Cube Jul 5, 2022

China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...

Company Deals

GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin

Fineline Cube Jul 4, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...

Company Deals

Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development

Fineline Cube Jul 4, 2022

China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB...

Posts pagination

1 … 609 610 611 … 621

Recent updates

  • Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials
  • InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials
  • Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China
  • Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication
  • Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Company Drug

Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.